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Abstract 
An antitumor agent of cytarabine (ara-C) was conjugated with a 2-oxopropyl group at N(4) 
position to obtain a radiation activated prodrug (oxo-ara-C) that targets hypoxic tumor tissues to 
show a selective cytotoxicity. The parent antitumor agent, ara-C, was confirmed to be released 
from oxo-ara-C via one-electron reduction upon hypoxic X-irradiation. The prodrug oxo-ara-C 
was of dramatically reduced cytotoxicity against human lung adenocarcinoma A549 cells relative to 
ara-C because of the effect of 2-oxopropyl substituent. In contrast, X-irradiation of hypoxic A549 
cells containing oxo-ara-C enhanced the cytotoxic effect, indicating that toxic ara-C was 




Cytarabine (1-beta-D-arabinofuranosyl-cytosine; ara-C) synthesized by Walwick and 
coworkers is a family of antimetabolites.1 This deoxycytidine analog undergoes phosphorylation by 
intrinsic kinases, and is subsequently incorporated into DNA during chain elongation mediated by 
polymerase, thereby resulting in the inhibition of DNA replication and elongation.2 Due to the 
highly cytotoxic effect, ara-C has been widely used as an antineoplastic and antiviral agent. 
However, ara-C has drawbacks in clinical applications: typically high dose of ara-C causes serious 
side effects such as encephalopathy and cerebellar dyfunction.3 Therefore, there has been a demand 
for giving a target specific feature to ara-C that could discriminate between tumor and normal cells 
for cytotoxicity. In view of a tumor-specific microenvironment of hypoxia as generated from an 
imbalance between supply and consumption of oxygen in solid tumor tissues,4 we have attempted to 
exploit a new class of antitumor prodrugs that targets a hypoxic microenvironment to show a 
selective antitumor effect.5  
We have thus far identified a series of 2-oxoalkyl groups as the effective substituents for 
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conjugation to nucleic acid derivatives that is removable by X-irradiation under hypoxic conditions 
in aqueous solution.6 An activation mechanism has been proposed by which the 2-oxoalkyl group 
undergoes one-electron reduction by hydrated electrons (eaq-)7 generated via radiolysis of water to 
form the corresponding π* anion radical, followed by thermal activation into the σ* anion radical 
and is readily hydrolyzed to release the 2-oxoalkyl group.8 We have applied these characteristics of 
the 2-oxoalkyl group to develop prodrugs of antitumor agents, 1-(2’-oxopropyl)-5-fluorouracil and 
2’-deoxy-5-fluoro-3-(2’-oxoalkyl)uridine, which are activated to release 5-fluorouracil (5-FU) or 
5-fluoro-2’-deoxyuridine (5-FdUrd), respectively, upon hypoxic X-irradiation.6  
In this study, we designed an ara-C derivative possessing a 2-oxopropyl group at N(4) 
position (oxo-ara-C) to obtain a novel radiation-activated prodrug. We performed the radiolytic 
one-electron reduction of oxo-ara-C and evaluated its cytotoxic effect under hypoxic conditions. 
The 2-oxopropyl group was readily removed from oxo-ara-C upon hypoxic X-irradiation. Analysis 
of cell viability with SF assay revealed that oxo-ara-C released the toxic parent ara-C via 




Results and discussion 
The synthesis of oxo-ara-C is outlined in Scheme 1. Triazole group of 19 was substituted 
with 1-amino-2,2-dimethoxypropane10 to give an acetal derivative 2. Hydrolysis of 2 furnished the 
desired oxo-ara-C. A control compound 3 without a carbonyl group at the N(4) position was 
prepared by the coupling of 1 with propylamine. 
We examined the efficiency of radiolytic one-electron reduction of oxo-ara-C for controlled 
releasing of ara-C in an argon-purged aqueous solution containing 2-methyl-2-propanol (10 mM) 
as the scavenger of oxidizing hydroxyl radicals (•OH).7,11 Under these radiolysis conditions, 
reducing hydrated electrons (eaq-) were generated as the major active species. Fig. 1 shows a 
representative reaction profile analyzed by HPLC of the radiolytic one-electron reduction of 
oxo-ara-C by the resulting eaq- under hypoxic conditions. The appearance of a single new peak in 
Fig. 1 was attributable to the formation of the parent ara-C, as confirmed by the overlap injection 
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of authentic samples in the HPLC analysis. The G values12 were 151 nmol J-1 for the decomposition 
of oxo-ara-C and 69 nmol J-1 for the formation of corresponding ara-C, respectively. Thus, 46% of 
the decomposed oxo-ara-C was converted to ara-C upon hypoxic X-irradiation. In contrast, the 
radiolytic decomposition of oxo-ara-C was dramatically suppressed under aerobic conditions; the 
G values were evaluated as 27 nmol J-1 for the decomposition of oxo-ara-C and 4 nmol J-1 for the 
formation of the corresponding ara-C, respectively. These results indicate that oxo-ara-C is 
activated to release ara-C in a hypoxia selective manner, as were observed in the cases of the 5-FU 
and 5-FdUrd prodrugs possessing 2-oxoalkyl groups.6,11 
To confirm the mechanistic validity of one-electron reduction of oxo-ara-C by eaq-, we 
conducted a control X-irradiation of oxo-ara-C in an aqueous solution purged with nitrous oxide 
(N2O)13 gas, which efficiently captures reducing species of eaq- to produce oxidizing species of •OH. 
As shown in Table 1, the formation of ara-C was suppressed to greater extent in the presence of 
N2O relative to the argon-purged aqueous solution, while efficient decomposition of oxo-ara-C 
occurred due to the •OH reaction (see also Fig. S1, S2.). Thus, it is reasonable to conclude that 
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reducing eaq- is essential for the activation of oxo-ara-C and the concomitant release of ara-C. 
In a separate experiment, we carried out radiolytic reduction of N(4)-substituted ara-C 
without a carbonyl group 3 in aqueous solution. As shown in Table 1, hypoxic irradiation of 3 failed 
to release ara-C, indicating that the carbonyl moiety is a key structural unit for the release of ara-C 
via one-electron reduction of oxo-ara-C by eaq-.  
Understanding of the function of oxo-ara-C in living cells is important for its biological 
applications. We therefore assessed the cytotoxicity of ara-C and oxo-ara-C toward A549 cells 
(human lung adenocarcinoma). A549 cells were cultured with various concentrations of ara-C or 
oxo-ara-C under aerobic conditions for 72 h, and subjected to a cell viability assay (Fig. 2). The 
IC50 values were 20.7 and 0.38 μM for oxo-ara-C and ara-C, respectively, indicating that a small 
modification of ara-C by a substituent such as the 2-oxopropyl group can effectively reduce the 
cytotoxicity of the parent antitumor agent. This result may be promising for further investigations to 
identify whether the dose of oxo-ara-C could be more increased without considerable side effects, 
compared to ara-C.  
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We subsequently exposed A549 cells to varying doses of X-ray in the presence or absence of 
oxo-ara-C under aerobic or hypoxic conditions, and characterized the hypoxia- and 
radiation-dependent cytotoxic effects of oxo-ara-C (Fig. 3). In accord with the suppression of 
cytotoxic effects as described above, the cells were viable even in the presence of 3.3 μM 
oxo-ara-C without X-irradiation (compare entries 1 to 2).14 Although the A549 cells were 
practically resistant to radiation under hypoxic conditions (entry 7), oxo-ara-C showed a striking 
property to significantly enhance the radiation sensitivity of A549 cells (entry 8). In contrast, 
oxo-ara-C had little effect on the radiation sensitibity under aerobic conditions (compare entries 5 
to 6). These results strongly suggest that oxo-ara-C preferentially released toxic ara-C via 
radiolytic one-electron reduction in hypoxic cells and thereby resulted in enhanced cytotoxicity, 
consistent with the radiation chemical reactivity.  
Thus, oxo-ara-C has been demonstrated to be useful as a radiation-activated prodrug that 
targets hypoxic tumor cells to show a cytotoxic effect. Incorporation of a 2-oxoalkyl group into 
ara-C dramatically reduced its cytotoxicity, while the toxic activity was recovered upon hypoxic 
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irradiation. Although the suppression mechanism of intrinsic cytotoxicity of oxo-ara-C in the 
presence of 2-oxoalkyl group remains unclear, it is presumable that the steric hindrance and/or 
disturbance of hydrogen bonding at N(4) position may inhibit the recognition of intracellular DNA 
polymerases, which are key enzymes involving in appearance of the cytotoxic effects of ara-C. In 
order to confirm this hypothesis, further mechanistic studies using DNA polymerase and 
triphosphate of oxo-ara-C are in progress.  
 
Conclusion 
In summary, we designed and synthesized an ara-C derivative possessing a 2-oxopropyl 
group at N(4) position (oxo-ara-C) as a radiation-activated prodrug. Oxo-ara-C was activated to 
release ara-C by eaq- as generated in radiolysis of water under hypoxic conditions. Assessment of 
the viability of A549 cells revealed that incorporation of 2-oxoalkyl group into ara-C resulted in a 
dramatic suppression of the cytotoxic effect, while hypoxic X-irradiation recovered the cytotoxicity 
via removal of the 2-oxoalkyl group to re-generate active ara-C. Thus, the ara-C derivatives 
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possessing 2-oxoalkyl groups are promising candidates as a new class of radiation-activated 




All reactions were carried out under a dry nitrogen atmosphere using freshly distilled solvents 
unless otherwise noted. Reagents were purchased from Aldrich, Wako pure chemical industries and 
Nacalai tesque, and used as received. Ultrapure water was obtained from YAMATO WR-600A. 
Precoated TLC (Merck silica gel 60 F254) plates were used for monitoring the reactions. Column 
chromatography was carried out on Wakogel C-300 (Wako pure chemical industries). 1H NMR 
spectra were measured with JOEL JMN-AL-300 (300 MHz) or JOEL JMN-AL-400 (400 MHz) 
spectrophotometers at ambient temperature. 13C NMR spectra were measured with JOEL 
JMN-AL-300 (75.5 MHz) or JOEL JMN-AL-400 (100 MHz) spectrophotometers at ambient 
temperature. Coupling constants (J values) are reported in Hertz. The chemical shifts are expressed 
in ppm downfield from tetramethylsilane, using residual methanol (δ = 3.30 in 1H NMR, δ = 49.0 in 
13C NMR) as an internal standard. Multiplicity is designed as singlet (s), doublet (d), triplet (t),  
doublet-doublet (dd), or multiplet (m). FAB Mass spectra were recorded on JOEL JMS-SX102A 
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spectrometer, using glycerol matrix. A Rigaku RADIOFLEX-350 was used for X-irradiation. 
High-performance liquid chromatography (HPLC) was performed with Shimadzu LC-6A system. 
Sample solutions were injected on a reversed phase column (Inertsil ODS-3, GL Science Inc., φ 4.6
×150 nm). The 0.1 M triethylamine (Et3N) 5 vol% acetonitrile/water solution containing acetic 
acid, pH 7.0 was delivered as mobile phase at a flow rate of 0.6 ml/min at 40 °C. The elution peaks 
were monitored at 260 nm wavelength. 
4-(2,2-Dimethyoxypropylamino)-1-(β-D-arabinofuranosyl)pyrimidine-2-(1H)-one (2)  
1-Amino-2,2-dimethoxypropane10 (796 mg 6.68 mmol) was added to a solution of 19 
(4-(1,2,4-Triazol-yl)-1-(β-D-2,3,5-tri-O-acetylarabinofuranosyl)pyrimidine-2(1H)-one, 167 mg, 
0.40 mmol) in dioxane (1.2 ml) and stirred for 9.5 h at 80 °C. The solvent was removed under 
reduced pressure. The crude product was purified by column chromatography (SiO2 6% 
methanol-chloroform) to give 2 (71 mg, 52%) as a white solid; mp 171–173 °C; 1H NMR (CD3OD,  
400 MHz) δ 7.75 (d, 1H, J = 7.6 Hz), 6.16 (d, 1H, J = 4.0 Hz), 5.93 (d, 1H, J = 7.6 Hz), 4.16 (dd, 
1H, J = 2.4, 3.6 Hz), 4.04 (dd, 1H, J = 2.4, 2.4 Hz), 3.92 (m, 1H), 3.79 (m, 2H), 3.58 (s, 2H), 3.23 (s, 
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6H), 1.28 (s, 3H); 13C NMR (CD3OD, 75.5 MHz) δ 165.9, 158.7, 143.0, 101.8, 95.7, 88.3, 86.4, 
78.2, 76.8, 62.8, 48.8, 48.8, 45.3, 20.5; FABMS (glycerol) m/z 346 [(M + H)+]; HRMS calcd. for 
C14H24N3O7 [(M + H)+] 346.1614, found 346.1611. 
4-propylamino-1-(β-D-arabinofuranosyl)pyrimidine-2-(1H)-one (3) 
Propylamine (0.23 ml, 2.80 mmol) was added to a solution of 19 
(4-(1,2,4-Triazol-yl)-1-(β-D-2,3,5-tri-O-acetylarabinofuranosyl)pyrimidine-2(1H)-one, 43.5 mg, 
0.103 mmol) in ethanol (0.3 ml) at room temperature. After 4.5 h the product was concentrated 
under reduced pressure. The crude product was purified by column chromatography (SiO2 1% Et3N, 
9% methanol-chloroform) to give 3 (21 mg, 71%) as a white solid; mp 194–195 °C; 1H NMR 
(CD3OD, 300 MHz) δ  7.72 (d, 1H, J = 7.5 Hz), 6.17 (d, 1H, J = 3.9 Hz), 5.79 (d, 1H, J = 7.8 Hz), 
4.16 (m, 1H), 4.07 (m, 1H), 3.93 (m, 1H), 3.80 (m, 2H), 3.32 (m, 2H), 1.60 (m, 2H, J = 7.2 Hz), 
0.96 (t, 3H, J = 7.2 Hz); 13C NMR (CD3OD, 100 MHz) δ 165.4, 158.6, 142.5, 95.6, 88.2, 86.3, 78.2, 
76.8, 62.8, 43.4, 23.3, 11.7; FABMS (glycerol) m/z 286 [(M + H)+]; HRMS calcd. for C12H20N3O5 
[(M + H)+] 286.1403, found 286.1394. 
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4-(2-oxopropylamino)-1-(β-D-arabinofuranosyl)pyrimidine-2-(1H)-one (4) (oxo-ara-C) 
2 (20 mg 0.058 mmol) was hydrolyzed by treatment with aqueous 1 M oxalic acid in THF 
(0.3 ml) at room temperature for 5 h. The solvent was evaporated under reduced pressure and the 
crude product was purified by column chromatography (SiO2 1% Et3N, 12% methanol-chloroform) 
to give oxo-ara-C (7.7 mg, 44%) as a white solid; mp 180–182 °C; 1H NMR (CD3OD, 300 MHz) 
δ  7.79 (d, 1H, J = 7.5 Hz), 6.15 (d, 1H, J = 3.8 Hz), 5.93 (d, 1H, J = 7.5 Hz), 4.26 (s, 2H), 4.16 (dd, 
1H, J = 2.4, 3.6 Hz), 4.04 (dd, 1H, J = 2.8, 2.6 Hz), 3.92 (m, 1H), 3.79 (m, 2H), 2.18 (s, 3H); 13C 
NMR (CD3OD, 75.5 MHz) δ 206.0, 165.6, 158.5, 143.4, 95.4, 88.4, 86.6, 78.2, 76.8, 62.8, 51.3, 
27.1; FABMS (glycerol) m/z 300 [(M + H)+]; HRMS calcd. for C12H18N3O6 [(M + H)+] 300.1196, 
found 300.1189. 
Radiolytic reduction 
Aqueous solutions of oxo-ara-C and 3 (100 μM), containing 2-methyl-2-propanol (10 mM), 
were purged with argon or nitrous oxide for 15 min and then irradiated in a sealed glass ampoule at 
ambient temperature with an X-ray source (4.0 Gy min-1). After the X-irradiation, the solution was 
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immediately subjected to HPLC analysis. 
Assessment of cytotoxicity toward A549 cells 
A549 cells were cultured in Dulbecco’s modified Eagle’s minimum essential medium 
(DMEM) containing 10% fetal bovine serum (FBS). The cells were seeded into 96-well plates 
(2000 cells/well) and cultured at 37 °C in a well-humidified incubator with 5% CO2 and 95% air 
(aerobic condition) for 24 hours. The cells were then incubated with the various concentrations of 
ara-C or oxo-ara-C under aerobic conditions for 72 hours, and added with 11 μL of Cell Count 
Reagent SF15 (nacalai, Japan). The plates were further incubated at 37 °C for 2 hours and the cell 
viability assay was performed using Microplate Reader (BIO-RAD). 
Radiation-induced cytotoxicity of oxo-ara-C 
A549 cells were seeded into 96-well plates (2000 cells/well) and incubated at 37 °C for 24 
hours under aerobic or hypoxic conditions. For the hypoxic treatment (< 0.02% of oxygen), the 
cells were treated in a hypoxic chamber, BACTRON-Ⅱ(Sheldon Manufacturing Inc., Cornelius, 
OR, USA). The plates kept under aerobic or hypoxic conditions using Anaeron Pack System 
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(Mitsubishi Gas Chemical Company Inc., Japan) were X-irradiated at a dose of 4 Gy and incubated 
for 72 hours under aerobic conditions. After adding 12 μL of Cell Count Reagent SF solution 
(nacalai, Japan) to each well, and the cell viability assay was performed as described above. 
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Scheme 1. Reagents and conditions: (a) 1-amino-2,2-dimethoxypropane, dioxane, 80 °C, 9.5 h (for 
2, 52%); propylamine, ethanol, room temperature, 4.5 h (for 3, 71%); (b) 2, oxalic acid, THF, room 







Fig. 1 HPLC profiles for the one-electron reduction of oxo-ara-C (100 μM) in the hypoxic 
X-radiolysis (0, 200, and 600 Gy) of aqueous solution containing 2-methyl-2-propanol (10 mM). 
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Table 1. G values for the decomposition of oxo-ara-C and for the formation of ara-C in the 





a Not detected 
 
  G value / nmol J-1 
Compound (saturating gas) Decomposition Formation 
oxo-ara-C (argon) 151 69 
oxo-ara-C (air) 27 4 
oxo-ara-C (nitrous oxide) 141 5 






Fig. 2 Cytotoxicity of ara-C and oxo-ara-C against A549 tumor cells. A549 cells were incubated 
with indicated concentrations of ara-C or oxo-ara-C under aerobic conditions for 72 hours. To 
calculate the cell viability in each conditions, SF counts (OD450) in each drug concentration were 
compared to those in minimal drug concentrations. ara-C: open square, oxo-ara-C: closed square. 






Fig. 3 Radiation-induced cytotoxicity of oxo-ara-C against A549 cells under hypoxic conditions. 
A549 cells were cultured in the presence (+) or absence (-) of 3.3 μM oxo-ara-C, and X-irradiated 
(4 Gy) under aerobic or hypoxic conditions. Results are shown with the mean ± S.D. n = 3 (* P < 
0.05. NS: not significant). 
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Fig. S1. Radiolytic reduction of 100 μM oxo-ara-C (closed square) to release ara-C (open square) 











Fig. S2. HPLC profiles for the X-radiolysis (0, 200, and 600 Gy) of oxo-ara-C (100 μM) in aerobic 
(a) and N2O-saturated (b) aqueous solutions containing 2-methyl-2-propanol (10 mM)  
 
